Skip to main navigation
Skip to search
Skip to main content
Sort by
Immunology and Microbiology
Mustela Putorius Furo
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Infectious Disease
74%
Infection
74%
Virus
67%
Rhesus Monkey
57%
Lung
49%
Virus Nucleocapsid
33%
Nairovirus
33%
Influenza
31%
Interferon Gamma
31%
Viral Shedding
30%
Influenza A Virus (H3N2)
30%
Caspase
29%
COVID-19
28%
Upper Respiratory Tract
27%
Neutralizing Antibody
27%
Influenza A Virus (H1N1)
26%
Crimean-Congo Hemorrhagic Fever Virus
23%
Adoptive Immunity
20%
T Cell
19%
Lymphocyte
18%
Ebola Virus
16%
Interferon-Stimulated Gene
16%
Protein Cleavage
16%
Bunyaviridae
16%
Influenza Virus
16%
TLR2
16%
Agonist
16%
Vesiculovirus
16%
Inactivated Vaccine
16%
Pseudotyping
16%
Human Immunodeficiency Virus 1
16%
Gene Expression
16%
Cross Protection
16%
Glycoprotein
16%
Macaca fascicularis
16%
Programmed Cell Death
16%
Quantitative Reverse Transcription Polymerase Chain Reaction
16%
Tick Borne Encephalitis Virus
16%
DNA Immunization
16%
Drug Dose Regimen
16%
Disease Burden
16%
Viral Disease
14%
Orthobunyavirus
10%
Ribonucleic Acid
8%
Replication
8%
Cross-Reactivity
8%
Immune Response
8%
Influenzavirus A
7%
Keyphrases
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
75%
Ferret
62%
Rhesus Macaque
50%
Challenge Model
33%
COVID-19
30%
Lung
26%
SARS-CoV-2 Challenge
22%
Hemorrhagic Fever Virus
20%
Nonhuman Primate
20%
Response to Infection
20%
Lung Pathology
19%
Ferret Model
19%
RT-qPCR Assay
16%
Tick-borne Encephalitis Virus
16%
Upper Respiratory Tract
16%
Pathological Outcomes
16%
H1N1 Subtype
16%
H3N2 Subtype
16%
DNA Vaccine
16%
Human Influenza
16%
Scottish
16%
ChAdOx1 nCoV-19
16%
Crimean-Congo Hemorrhagic Fever
16%
Cynomolgus Macaque
16%
TLR2
16%
Protective Immunity
16%
Cellular Immune Response
16%
Federal Republic
16%
Republic of Sudan
16%
One Dose
16%
Lyme Borreliosis
16%
Acute Undifferentiated Febrile Illness
16%
Disease Model
16%
Ribavirin Treatment
16%
Respiratory Infection
16%
Genetic mutation
16%
Next-generation Sequencing
16%
Formalin-inactivated Vaccine
16%
Synthetic DNA
16%
Two-dose
16%
2-dose
16%
INO-4800
16%
Disease Burden
16%
Viral Development
16%
Immunological Outcomes
16%
Dose-dependent Response
16%
Tayside
16%
Dosing Regimen
16%
Virus
15%
Vaccine Candidate
15%
Medicine and Dentistry
Ebolavirus
36%
Virus
34%
Viral Hemorrhagic Fever
22%
Quantitative Reverse Transcription Polymerase Chain Reaction
20%
Diseases
20%
Toll Like Receptor 2
16%
Ribavirin
16%
Virus Glycoprotein
16%
Upper Respiratory Tract
16%
Crimean-Congo Hemorrhagic Fever
16%
Human Immunodeficiency Virus 1
16%
Next Generation Sequencing
16%
Gene Mutation
16%
Vesiculovirus
16%
Virus Shedding
16%
Intranasal Drug Administration
16%
Cohort Analysis
16%
Severe Acute Respiratory Syndrome Coronavirus 2
16%
Tick Borne Encephalitis Virus
16%
Neutralizing Antibody
16%
Hemorrhagic Fever
13%
Crimean-Congo Hemorrhagic Fever Virus
10%
Pathogen
10%
Virus Infection
9%
Tropical Disease
8%
Infection
8%
Mutagenic Activity
6%
Etiology
6%
Case Fatality Rate
6%
Public Health
6%
Bleeding
6%
